Enhancing Systematic Reviews: AI Literature Review Integration for Efficiency and Rigor

By João L. Carapinha

February 23, 2026

AI Literature Review Integration is transforming systematic literature reviews (SLRs), as outlined in this preprint. It provides methodological guidance for incorporating artificial intelligence (AI) into SLRs with a human-in-the-loop approach to maintain scientific rigor. AI accelerates resource-intensive stages like screening and data extraction while tackling risks such as bias, hallucinations, and lack of transparency. The core argument is that AI complements human judgment, enabling faster, scalable evidence synthesis aligned with PRISMA and Cochrane standards, without replacing expert oversight.

Tackling SLR Workload Bottlenecks

There are operational challenges in traditional SLRs, which require months of manual effort to screen thousands of records amid exploding scientific output. This leads to extended timelines, workforce strain, and outdated reviews post-publication. AI Literature Review Integration delivers key advantages, including over 50% reductions in completion time across 17 of 25 studies, five- to sixfold decreases in abstract screening duration, and 55%–64% fewer abstracts needing human review, per a pragmatic review. These efficiencies enable scalability for large evidence bases, like sourcing parameters for economic models in health economics and outcomes research (HEOR), while reducing human error in repetitive tasks and improving pattern detection. Vigilant human validation counters AI biases from training data, preserving methodological integrity.

Human Oversight in AI-Driven SLR Stages

The preprint emphasizes human oversight to address AI limitations, offering structured guidance for AI Literature Review Integration across SLR stages, drawn from authors’ experience and literature. It follows the Cochrane Handbook’s process—from research question definition to reporting—via a detailed table. AI prioritizes records for title/abstract screening through relevance ranking refined by human feedback, generates search strings with synonyms and MeSH terms, and extracts structured PICO elements, validated against gold-standard datasets. Rigor uses metrics like precision, recall, F1 score, pilot testing, and inter-reviewer reliability (Cohen’s kappa 0.77–0.88). Tools like RobotReviewer handle risk-of-bias assessments, while NLP-ML platforms aid PRISMA diagrams. Protocols ensure transparency with dual AI-human screening, spot checks, and PRISMA standards.

Reference url

Recent Posts

PIONEER TEENS Trial Reveals Oral Semaglutide Diabetes Breakthrough for Pediatric Patients

By João L. Carapinha

April 24, 2026

Important results from the PIONEER TEENS phase 3a trial! Oral semaglutide diabetes therapy delivered statistically superior glycemic control compared with placebo in children and adolescents aged 10–17 years with type 2 diabetes. The trial met its primary endpoint with a 0.83% greater reduction i...
Terminal Complement Inhibition: Promising Results in IgAN from the I CAN Trial
Terminal complement inhibition with Ultomiris (ravulizumab) delivered a statistically significant and clinically meaningful reduction in proteinuria at week 34 in adults with immunoglobulin A nephropathy (IgAN) at high risk of progression. According to the prespecified interim analysis of the Pha...
Advancements in Rare Disease Therapies: CHMP’s April 2026 Insights and Economic Implications
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommendations from its 20–23 April 2026 meeting, included a particular focus on rare disease therapies. The CHMP issued positive opinions for five new medicines, three of which carry orphan designation, alo...